Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.

Abstract: The present invention relates to a method and a DNA nanostructure for detecting a target structure. In particular, the present invention relates to a DNA nanostructure, which ensures a preferably linear dependence on the number of marker molecules and the measurement signal regardless of the physical arrangement of a plurality of such DNA nanostructures by virtue of the skilled selection of the shape of the DNA nanostructure and the placement of the marker molecules attached to it. The invention additionally relates to the use of said DNA nanostructures and other nanoreporters, preferably in combination with adapters which bind specifically to target molecules, in a method for quantifying a plurality of target molecules, preferably in a simultaneous manner, using a multiplex method.

Abstract: The present invention relates to novel hydrolytically stable carbon-cyclic 5-aza-2-deoxycytidine and carbocyclic 5-aza-cytidine compounds and pro-drugs thereof as hypomethylating agents.

Abstract: The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N—H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N?,N?-tetrakis-(2-hydroxyethyl) adipinic acid amide.

Abstract: The present invention relates to compositions comprising a therapeutic protein with enhanced stability, which comprise a piperazine- or morpholine-containing zwitterionic buffering substance, such as HEPES, in particular when used out of the common pH range. The compositions of the invention are particularly useful for topical administration The present invention further relates to the use of said compositions for treating bacterial infections, e.g. bacterial infections caused by Staphylococcus aureus such as methicillin-resistant Staphylococcus aureus (MRSA). The present invention further relates to the use of said compositions for preventing or eliminating nasal bacterial colonization or bacterial colonization of the skin.

Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention relates to a novel molecule comprising three binding sites with specificity for a tumor cell, for an effector cell and for a checkpoint molecule, respectively. Moreover, the present invention relates to a pharmaceutical composition comprising such a molecule and to uses of such a molecule.

Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process tor the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).

Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to methods of determining the sequence of nucleotides in target nucleic acid molecules. Thus, the invention relates to methods of sub-unit sequencing. The methods comprise the use of identification nucleic acid detection entities which specifically hybridize to the target nucleic acid, bind identification tags and have localization tags transiently bind thereto.

Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.

Abstract: This disclosure provides new animal models for studying Usher syndrome and developing new therapy. The technology is implemented in pigs, and other large animals in which the ophthalmic architecture and function more closely resembles architecture and function of the human eye. The animals have a genetic modification in which all or a portion of a human gene known to cause Usher syndrome in human patients replaces the host gene. Animals can be cloned or bred to be homozygous at the targeted locus, whereupon they manifest symptoms and signs of Usher syndrome. Since a substantial portion of the targeted gene has been humanized, the animals can be used to develop and test pharmacological agents such as gene therapy that are sequence dependent.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.

Abstract: Disclosed is a method of determining information regarding the location of energy deposition of an ion beam, in particular a proton beam, in an absorptive medium, in particular in the tissue of a patient undergoing radiation therapy, comprising the following steps: generating an intensity modulated ion beam, wherein the intensity modulation comprises one or more modulation frequency components, detecting an acoustic signal attributable to the time dependent energy deposition in said absorptive medium by said intensity modulated ion beam using at least one detection apparatus, said detection apparatus being preferably configured for extracting at least one modulation frequency component of the acoustic signal corresponding to a respective one of the one or more modulation frequency components of said intensity modulation, or a harmonic thereof, and deriving information regarding the location of the energy deposition based, at least in part, on a time lag between the timing of the intensity modulation of sai

Abstract: A method for investigating one or a plurality of phase objects is described, in which a grid made up of elements is used, which is illuminated with light of a light source, the coherence length of which is larger than the average spacing of adjacent elements of the grid. A diffraction image of the illuminating light scattered on the grid is generated, whereby the one or the plurality of phase objects are placed in the light path between the light source and the grid and/or in the light path of the illuminating light scattered on the grid. At least a part of the diffraction image is detected by an optical sensor directly or after interaction with further optical components and converted into a signal. The signal is analyzed further in order to ascertain information relating to the one or plurality of phase objects therefrom. A corresponding device is likewise described.